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Highlights 
Peptide stapling of the neuropeptide orexin-A15–33 lowers the potency significantly. 
The peptide C-terminus is crucial for activity, and modifications were not allowed. 
Central and N-terminal modifications yielded bioactive peptides. 
 
Abstract 
The peptides orexin-A and -B, the endogenous agonists of the orexin receptors, have similar 
19-amino-acid C-termini which retain full maximum response as truncated peptides with only 
marginally reduced potency, while further N-terminal truncations successively reduce the activity. 
The peptides have been suggested to bind in an α-helical conformation, and truncation beyond a 
certain critical length is likely to disrupt the overall helical structure. In this study, we set out to 
stabilize the α-helical conformation of orexin-A15–33 via peptide stapling at four different sites. At a 
suggested hinge region, we varied the length of the cross-linker as well as replaced the staple with 
two α-aminoisobutyric acid residues. Modifications close to the peptide C-terminus, which is 
crucial for activity, were not allowed. However, central and N-terminal modifications yielded 
bioactive peptides, albeit with decreased potencies. This provides evidence that the orexin receptors 
can accommodate and be activated by α-helical peptides. The decrease in potency is likely linked to 
a stabilization of suboptimal peptide conformation or blocking of peptide backbone–receptor 
interactions at the hinge region by the helical stabilization or the modified amino acids. 
 
Abbreviations 
Aib, α-aminoisobutyric acid; Fmoc, fluorenylmethyloxycarbonyl; HPLC, high-performance liquid 
chromatography; HBM, Hepes-buffered medium 
 
Keywords 
peptide stapling; pseudopeptide; orexin; G protein-coupled receptor 
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1. Introduction 
The neuropeptides orexin-A and -B regulate energy homeostasis, the reward system, and the sleep–
wake patterns through the G protein-coupled OX1 and OX2 receptors [1–4]. Drug discovery for the 
orexinergic system has mainly concentrated on insomnia [3]. Several small molecule orexin 
receptor antagonists have been developed as hypnotics; thus far one, suvorexant, has reached the 
market [5]. In contrast, only few non-peptide agonists have been reported [6–9]. Both orexin 
receptors have recently been crystallized with non-peptide antagonists [10,11]. 
Human orexin-A is a 33-amino-acid peptide with C-terminal amidation, N-terminal pyroglutamyl 
cyclization and two disulfide bridges (Cys6–Cys12 and Cys7–Cys14) [1]. Orexin-B is a linear 
28-amino-acid peptide with C-terminal amidation [1]. The C-termini of the peptides are highly 
conserved as 13 of the 19 C-terminal amino acids are identical (Fig. 1A). In aqueous solution, 
orexin-A exhibits three helical segments (residues 6–9, 16–23 and 25–32) [12,13], and orexin-B 
two helical segments (residues 7–19 and 23–28) [14](Fig. 1A). In orexin-A, the turn between the 
N-terminal helix and the middle helix is stabilized by the disulfide bridges. Both peptides feature a 
flexible “hinge” between the C-terminal helix and the adjacent helix (Fig. 1A). NMR studies have 
identified two distinct bent conformations and one straight conformation for orexin-A [12,13], and 
one bent conformation for orexin-B [14]. It has been postulated that receptor binding would also 
take place in one of these conformations [15,16], yet despite efforts, the bioactive conformation and 
the binding mode remain to be experimentally confirmed. 
The conserved C-terminus is critical for the biological activity, and while N-terminal truncation 
down to 19 residues is tolerated with only a modest reduction in potency, further shortenings lead to 
successive loss of activity [17–20]. We speculate this to be due to disruption of the secondary 
structure, especially since the residues eliminated in this further truncation (orexin-A: Arg15–
Leu19; orexin-B: Arg10–Leu14) can be individually mutated to alanine without a similar loss of 
biological activity [18–21]. We set out to investigate whether an introduction of a conformational 
constraint in orexin-A15–33 was allowed, and if successful, whether this could allow further 
truncation of the peptide. We employed the hydrocarbon stapling technology, a macrocyclization 
strategy that involves an introduction of two non-natural amino acids, each having a side chain with 
a terminal alkene group, followed by a ring-closing metathesis reaction between these side chains 
[22]. Successful stapled ligands towards protein–protein interaction targets such as Bcl-2 and the 
p53-inactivating proteins MDM2 and MDMX, and even towards G protein-coupled receptors such 
as neuropeptide Y and galanin receptors, highlight that the position and length of the hydrocarbon 
staple are critical for successful stabilization of an α-helical conformation [23]. In addition to 
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prospects of successful further truncation of the orexin peptides, macrocyclization of linear peptides 
can enhance proteolytic stability of peptides, which would be beneficial for drug development. 
We selected four sites in orexin-A15–33 (Fig. 1B, Table 1) to probe the effects of helical stabilization 
and the available space for the cross-linker. Orexin-A features distinctive hydrophobic and 
hydrophilic sides, which may be required for membrane interactions and receptor binding 
[13,20,24]. To avoid disturbing this, we preferred placing the hydrophobic staple at the hydrophobic 
side, even though many hydrophobic residues are important for bioactivity [17–21]. Our first choice 
for introducing a staple was a pair of alanine residues (Ala23 and Ala27) at the peptide hinge region 
(site 3 in Fig. 1B). Secondly, we selected Ala27 and Leu31 near the C-terminus (site 1 in Fig. 1B), 
as a staple near the end of the helix might reduce helical fraying and result in stabilization. The 
peptide C-terminus is expected to penetrate into the receptor cavity [16–20], but as leucine has a 
bulky side chain, we supposed that there might be sufficient space for the hydrocarbon staple (Fig. 
2A). Thirdly, we placed a staple at Leu19 and Ala23 at the N-terminus of the peptide fragment (site 
4 in Fig. 1B). This part of the peptide is expected to reside beside the extracellular loops of the 
receptor [16], where there should be more space and flexibility to accommodate the staple. 
However, this staple would not permit us to truncate further than to orexin-A19-33, thus countering 
our secondary aim of producing shorter biologically active orexin peptide fragments. Our fourth 
stapling site was at Asn25 and Gly29, on the hydrophilic face of the helix (site 2 in Fig. 1B). 
Previous studies suggest that Asn25 could be replaced with alanine without a marked loss on 
activity [17,18]. However, we were doubtful whether the introduction of hydrophobic bulk at a 
polar side of the helix would be tolerated, especially as replacing Gly29 with alanine is not allowed 
[17,19–21]. 
Fig. 1. (A) Sequence alignment of the orexin peptides. Lines show the disulfide bridges, and boxes the 
helical segments [13,14]. X = pyroglutamic acid. (B) Schematic representation of the sites for helical 
stapling in orexin-A15–33. Peptide N-terminus (R15) is on the left, and modification sites are numbered 
starting from the C-terminus. The flexible hinge region is shaded in grey.  
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Table 1 
Sequences of the synthetic peptides 
Compound Stapling 
 Amino acid position in orexin-A  
 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33  
Ac-orexin-A15–33 Linear Ac- R L Y E L L H G A G N H A A G I L T L -NH2 
Orexin-A15–33 Linear  R L Y E L L H G A G N H A A G I L T L -NH2 
1A Stapled Ac- R L Y E L L H G A G N H X5 A G I X5 T L -NH2 
1AL Linear  R L Y E L L H G A G N H X5 A G I X5 T L -NH2 
2A Stapled Ac- R L Y E L L H G A G X5 H A A X5 I L T L -NH2 
3A Stapled Ac- R L Y E L L H G X5 G N H X5 A G I L T L -NH2 
3B Stapled Ac- R L Y E L L H G X4 G N H X7 A G I L T L -NH2 
3C Stapled Ac- R L Y E L L H G X7 G N H X4 A G I L T L -NH2 
3D Stapled Ac- R L Y E L L H G X4 G N H X5 A G I L T L -NH2 
3DL Linear  R L Y E L L H G X4 G N H X5 A G I L T L -NH2 
3EL Linear Ac- R L Y E L L H G Aib G N H Aib A G I L T L -NH2 
4A Stapled Ac- R L Y E X5 L H G X5 G N H A A G I L T L -NH2 
Modified residues are in bold. XN: a stapling residue with side-chain length of N atoms 
Fig. 2. Size comparison of the wild-type residues (in orange) and the modifications (grey) in orexin-A15–33. 
(A–C and E) Sites 1–4 with an eight-atom staple, (D) site 3 with an Aib-modification. The peptide 
conformation shown here is the straight helical conformation determined by Takai et al. [13] for this region 
of the full-length orexin-A. The left-hand face of the peptide features a hydrophobic wall. 
2. Materials and Methods 
2.1. Stapling site design and images 
Stapling sites were designed, three-dimensional space requirements estimated, and the 3D figures in 
the article generated with Discovery Studio 4.5 (Dassault Systèmes BIOVIA, San Diego, CA, USA) 
and PyMOL 1.7.0.0. (Schrödinger, LLC, New York, NY, USA). 
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2.2. Peptide synthesis and purification 
The peptides were synthesized manually in a plastic syringe fitted with a filter on Rink Amide AM 
resin in 0.05 mmol scale using fluorenylmethyloxycarbonyl (Fmoc) -chemistry. The alkene-
containing side chains for ring-closing metathesis reaction were introduced by using Fmoc-(S)-N-
Fmoc-2-(3’-butenyl)alanine, (S)-N-Fmoc-2-(4’-pentenyl)alanine and (S)-N-Fmoc-2-(6’-
heptenyl)alanine as amino acids in the peptide synthesis, depending on the desired length of the 
cross-linker; two (4-pentenyl)alanines gives the canonical α-helix-stabilizing staple. The ring-
closing metathesis reaction was performed on the Fmoc-protected on-resin peptide with Hoveyda-
Grubbs 2nd generation catalyst in anhydrous 1,2-dichloroethane in a microwave tube. The reaction 
mixture was bubbled with argon for 30 min at room temperature, and then the sealed tube was 
heated in the microwave cavity at 100 °C for 60 min without stirring; for these peptides, standard 
reaction conditions with argon-bubbling at room temperature did not lead to a high conversion of 
the ring-closing metathesis reaction. The Fmoc-group was removed after ring-closing metathesis 
and the peptides were acetylated with dimethylformamide:acetic anhydride:diisopropylethylamine 
(90:10:1) prior to cleavage from the resin with trifluoroacetic acid:H2O:1,2-
ethanedithiol:triisopropylsilane (94:2.5:2.5:1). Those peptides that were not ring-closed or 
acetylated did not undergo these reactions. The yield of crude peptides after cleavage from resin, 
followed by precipitation with diethyl ether, was 39–72%. The peptides were purified to a minimum 
purity of 90% by preparative high-performance liquid chromatography (HPLC) followed by 
identity verification by mass spectrometry and purity analysis by analytical HPLC. After 
purification, the total yield for linear peptides was 4.4–14% and for ring-closed 1.0–6.7%. More 
detailed description of the synthesis is available in the Supplemental Material. The resulting 
peptides are summarized in Table 1. 
2.3. Cell culture 
CHO-hOX1 and -hOX2 cells [18,25] were cultured in Ham’s F12 medium (Gibco/Life 
Technologies, Paisley, UK) supplemented with 10% (v/v) fetal calf serum, 100 U/ml penicillin G 
(Sigma-Aldrich, St. Louis, MO, USA) and 80 U/ml streptomycin (Sigma) at 37°C in 5% CO2 in an 
air-ventilated humidiﬁed incubator on plastic culture dishes (56 cm2 bottom area; Greiner Bio-One 
GmbH, Frickenhausen, Germany). For Ca2+ measurements, the cells were plated on 
polyethyleneimine-coated (25 μg/ml for 1 hour at 37°C; Sigma-Aldrich) black, clear-bottom half-
area Cellstar µClear 96-well cell culture plates (Greiner).  
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2.4. Experimental medium 
Hepes-buffered medium (HBM) was used as the experimental medium for cell experiments. It was 
composed of 137 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.44 mM KH2PO4, 4.2 mM NaHCO3, 
1 mM CaCl2, 10 mM glucose, and 20 mM HEPES, pH 7.4 with NaOH. Stripped bovine serum 
albumin [0.1% (w/v)] [26] was added to reduce possible attachment of the ligands to the plastic, and 
1 mM probenecid [p-(dipropylsulfamoyl)benzoic acid] to inhibit extrusion of the Ca2+ indicator. 
2.5. Drugs 
Probenecid [p-(dipropylsulfamoyl)benzoic acid] was from Sigma-Aldrich and human orexin-A 
from NeoMPS (Strasbourg, France). 
2.6. Pharmacological analysis 
The ability of the synthetic ligands to elevate intracellular Ca2+ concentration in human OX1 or OX2 
receptor-expressing cells was used as a measure of agonistic activity on orexin receptors [8,18,27], 
and the ability of the synthetic ligands at subeffective concentrations to inhibit orexin-A response as 
a (semiquantitative) measure of antagonistic activity. Ca2+ elevations were measured as described 
[8]. The cells, 1.5×104 per well, were plated on black, clear-bottom half-area 96-well plates. 
Twenty-four hours later, cell culture medium was removed and the cells were loaded with the 
loading solution composed of FLIPR Calcium 4 Assay Kit (Molecular Devices, Sunnyvale, CA, 
USA) dissolved in and diluted with HBM + 1 mM probenecid, for 60 min at 37 ºC. Then, the plate 
was placed in a FlexStation 3 fluorescence plate reader (Molecular Devices) and the intracellular 
Ca2+ levels were measured as fluorescence changes (excitation at 485 nm, emission at 525 nm) at 
37 ºC. A recording was made approximately every 1.9–2.4 s. Each well was measured for 180–
210 s with 30 s of baseline before stimulation (orexin-A or other ligands in 10-fold dilution series). 
This experimental setup gave the agonistic property of the ligands. Orexin-A was always tested in 
parallel to the synthetic ligands to allow evaluation of cell responsiveness and normalization to the 
orexin response (Fig. 3). Every concentration-response curve in each independent experiment was 
separately curve-fitted to Equation (1) [28]. 
response =  
[compound]n × responsemax
[compound]n+EC50
n   (1) 
The EC50-values obtained were converted to logEC50-values and normalized to the logEC50-value of 
orexin-A [logEC50(compound)  logEC50(orexin-A)] in each batch of cells before averaging the 
values from different experiments (Fig. 3). However, there was not much variation in the EC50 of 
orexin-A between the independent experiments (see Results). 
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Secondly, we assessed the antagonistic ability of the synthetic ligands [8,18]. Each plate was rerun 
in FlexStation 3 (approximately 60 min after the first run). The scheme was as above, but all wells 
with the synthetic ligands were stimulated with 0.1–0.3 nM orexin-A. The concentration of orexin-
A was chosen close to the EC50-value to give a robust response yet sensitive to antagonism. 
Calcium measurements were performed in triplicate or quadruplicate. All the values are given as 
mean ± sem. n indicates number of independent experiments; each experiment was repeated at least 
3 times. Statistical significance was evaluated using Student's two tailed paired t test. All data 
analyses, including curve-fitting and t test, were performed with Microsoft Excel (Microsoft Co., 
Redmond, WA, USA). 
3. Results 
Full-length orexin-A showed a robust Ca2+ response with an EC50 of 0.12 nM in both OX1- and 
OX2-expressing cells (logEC50 = −10.0 ± 0.08, n = 8, for both OX1 and OX2). Data with all other 
ligands were normalized to orexin-A responses measured in parallel. Truncation to orexin-A15–33 
resulted in a 6-fold and 7-fold (5.9 ± 2.0 and 6.9 ± 2.5 -fold, n = 3) reductions in potency for OX1 
and OX2, respectively, while the N-terminally acetylated truncated peptide (Ac-orexin-A15–33) was 
slightly more potent (p < 0.05) with a 4-fold (3.5 ± 0.74 and 4.1 ± 1.7 -fold, n = 3) decrease in 
potency in comparison to orexin-A (Fig. 3B). Both fragments produced the same maximal response 
as orexin-A (Fig. 3A). 
Introduction of the typical α-helix-stabilizing staple of eight atoms into Ac-orexin-A15–33 
(compounds 1A, 2A, 3A and 4A; Table 1) was unfavorable for the biological activity (Figs. 3 and 
4). Within the tested concentration range (up to 20 µM), only compound 4A was able to elicit the 
same maximal response as the full agonists orexin-A and orexin-A15–33, with 610–980-fold decrease 
in potency in relation to Ac-orexin-A15–33. Compounds 1A and 3A did not reach response saturation 
at the maximum concentration of 20 µM; for these, responses at 20 µM are given in Fig. 3. 
Compound 1A was extremely weak at OX1 and inactive at OX2, while compound 2A was inactive 
at both receptors. Assuming that compound 3A is a full agonist, it would show approximately 
57 000-fold (OX1) and 6700-fold (OX2) reductions in potency in relation to Ac-orexin-A15–33. 
At site 3, we tested cross-linkers that were either one carbon atom longer (compounds 3B and 3C) 
or shorter (compound 3D) than the typical α-helix-stabilizing staple of eight atoms. None of these 
compounds reached response saturation at 20 µM (Fig. 4), but if one assumes that these are full 
agonists, these compounds show 4800–76 000-fold decreases in potency in relation to 
Ac-orexin-A15–33 (Fig. 3). 
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Fig. 3. Potency as logEC50 (A) and maximal response (B) of the compounds in relation to orexin-A. Error 
bars show standard error of the mean. n = 3, except for orexin-A (n = 8), and for 1A, 3D, 3DL, and 4A 
(n = 4). 
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Fig. 4. Concentration-response curves for the tested ligands. n = 3, except for orexin-A (n = 8), and for 1A, 
3D, 3DL, and 4A (n = 4). Non-normalized data were averaged and then normalized to the logEC50 of 
orexin-A. 
To assess the effect of the cross-linking between the unnatural amino acids, we set out to purify the 
reaction intermediates prior to the ring-closing metathesis reaction for biological testing. From 
samples originally taken aside for analysis, we purified two linear intermediates: precursors of 
compounds 1A and 3D, which were named 1AL and 3DL, respectively (Table 1). Compound 1AL 
appeared slightly more potent than compound 1A at OX1 (Figs. 3 and 4), but the difference was not 
significant. Like compound 1A, compound 1AL was inactive at OX2. Site 3 showed a similar trend, 
with compound 3DL being slightly more potent than the stapled 3D at both receptors (Figs. 3 and 4), 
but the small difference was only significant (p<0.05) at OX2. 
To test if the problem lay with the unnatural side chains of the cross-linking residues, we 
synthesized a derivative of Ac-orexin-A15–33 in which Ala23 and Ala27 (site 3) were replaced by 
α-aminoisobutyric acid (Aib) residues (compound 3EL; Fig. 2D, Table 1). Aib features the same 
disubstituted α-carbon as the stapling residues – in essence it has the side chains of both L- and 
D-alanine – and it too promotes helicity [29]. Compound 3EL was a full agonist with 2200-fold 
(OX1) and 1600-fold (OX2) decreases in potency in relation to Ac-orexin-A15–33 (Figs. 3 and 4). 
To assess whether the structural modifications affect the binding itself (affinity) or ability to 
activate the receptor (efficacy), we also analyzed the synthetic peptides for possible antagonistic 
properties. Cells pre-treated with subeffective concentrations (10-fold below the first concentration 
giving a response) of modified peptides and then exposed to 0.1–0.3 nM orexin-A showed that none 
of the modified peptides inhibited orexin-A response (data not shown), which indicates that the 
structural modifications impair the binding affinity. 
4. Discussion 
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The potency of full-length orexin-A was in line with previous studies [27], and also the 4–7-fold 
reduction in potency associated with truncation to orexin-A15–33 is well in line with some previous 
reports [18,19], while greater decrease in potency has also been reported in other studies [17,30]. 
The typical eight-atom stapling was detrimental to the biological activity of orexin-A15–33, and 
consistent with the results of the site-directed mutagenesis studies [17,19–21], the effect was greater 
towards the peptide C-terminus. The staples in compounds 1A and 2A were clearly not allowed, as 
these compounds were (virtually) inactive. For compound 2A, this was to be expected, as it 
introduced a hydrophobic staple at a hydrophilic site, and also because the replaced Gly29 is 
important for bioactivity [17,19–21]. In compound 1A, the staple replaces Leu31, which also is 
required  in correct orientation  for the activity [17,19–21]. While the staple should mostly 
occupy the same space as the wild-type residue (Fig. 2A), it clearly is not a suitable replacement. 
However, in compounds 3A and 4A, the replaced residues should have been non-essential for 
receptor activation [18,21], but we still observed marked decreases in potency. We reasoned that 
there were three likely alternatives: the stabilized conformations were suboptimal, or the 
conformational rigidity or the added bulk of the staples was detrimental to receptor binding or 
activation. 
As the NMR-studies on orexin peptides have pointed out different conformations, especially in the 
“hinge” region (site 3 in Fig. 1B) [12–14], we decided to probe them with cross-linkers that were 
either one carbon atom longer (compounds 3B and 3C) or shorter (compound 3D). As the potencies 
of these compounds were of the same magnitude with the compound 3A, the conformations were 
apparently still unsuitable or the problem indeed lay in the added bulk of the cross-linker. To assess 
this further, we tested whether the linear precursor peptides, which carried the same unnatural 
amino acid substitutions but were not cross-linked, would have been more potent. We reasoned that 
although the unnatural amino acid residues with two alkyl substituents on the α-carbon promote 
helicity even without the cross-linking, the unlinked side chains can rotate freely and adopt better to 
the receptor's binding site. As the linear compounds 1AL and 3DL were slightly more potent than 
their ring-closed counterparts 1A and 3D, it appears that the ring closure was indeed unfavorable. 
However, as the linear compounds were still much weaker than Ac-orexin-A15–33, the main cause 
for the potency decrease at these sites was clearly not the cross-linking step, but the introduction of 
the cross-linking residues per se. 
Since the unnatural amino acid residues used in the cross-linking were poorly tolerated, we 
synthesized the Aib-derivative 3EL, in which the wild-type alanines at site 3 were replaced by Aib 
residues, which – like the cross-linking residues – feature disubstituted α-carbons to promote 
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helicity [29]. The compound 3EL was the most potent among compounds that carried a modification 
at site 3 – though still weaker than compound 4A. In comparison to the linear 3DL with 4-pentenyl 
and 3-butenyl side chains, 3EL with methyl side chains is 5–12-fold more potent. This suggests that, 
at least at this site, one of the problems with stapling lies with the bulk of the side chains, which 
may interfere with the peptide–receptor interactions. However, as also 3EL was significantly less 
potent than the parent peptide Ac-orexin-A15–33, something in the double Ala-to-Aib replacement 
must be detrimental to bioactivity, even though Aib should only take a little more space than 
alanine (Fig. 2D). Since the only difference as compared to the wild-type L-alanine is a methyl 
group instead of a hydrogen atom at the α-carbon, there is a limited number of possible causes for 
the decrease in potency (see below). 
Our original hypothesis was that the C-terminus of the orexin peptides would interact with the 
cognate receptors in a straight α-helical conformation, and that stabilization of that conformation 
would be beneficial for biological activity. However, it now seems likely that this hypothesis might 
be incorrect, and that the stabilization, at least with the methods we have used here, in fact impairs 
the peptide’s ability to bind to, or to activate their receptors. While the stapled peptides 3A, 3B, 3C, 
3D and 4A show that the receptor can accommodate and be activated by α-helical peptides, the 
stapling clearly decreases the potency. The linear compounds 1AL and 3DL show that the unnatural 
stapling amino acids themselves are poorly tolerated, and the Aib-variant 3EL highlights the 
disubstituted α-carbon as a likely culprit. It is possible that the peptide needs to adopt a specific bent 
conformation or that a certain degree of conformational flexibility is beneficial for binding to or 
activation of the receptor, while our modifications stabilize the α-helix and restrict flexibility. It is 
also possible that the additional methyl groups at the α-carbons present steric hindrance for peptide–
receptor interactions involving the peptide backbone. 
We only used Ca2+-elevation as a measure for orexin-receptor-mediated activity. While this 
Gq-mediated pathway is suggested to reflect the main physiological coupling [31], we cannot rule 
out biased signaling; i.e. even though the modified peptides show marked drops in potency for 
Ca2+-elevation, they might be more potent in activating other pathways. However, as our assay for 
antagonistic properties implies that our modified peptides are weak binders, it seems implausible 
that they would be very potent with respect to another signal pathway either. 
All the staples we introduced into the orexin-A15–33 spanned one helical turn (i, i+4), whereas for 
some peptides, i, i+7 stapling spanning two helical turns is better [22]. Given that modifications in 
the peptide C-terminus were poorly tolerated, i, i+7 stapling could be tried closer to peptide 
N-terminus, perhaps at Leu19–His26 or Leu20–Ala27, even though Leu20 is important for receptor 
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activation. However, if the helical stabilization itself is detrimental to the binding or efficacy of the 
peptide, the location or configuration of the staple should not alleviate this. 
Peptide stapling has mostly been utilized to interfere with protein–protein interactions, which often 
take place over large surface areas, where potential binding sites are shallow grooves easily 
accessible from the solvent. In these cases, one side of the peptide helix is often not in contact with 
the target protein, leaving ample space for the staple. In only few cases stapled peptides, namely 
those based on galanin and neuropeptide Y, have been reported to activate G protein-coupled 
receptors [32]. The bioactive N-terminal fragment of galanin, galanin1–16, was stabilized with 
central or C-terminal staples together with increased cationization at the C-terminus, and 
neuropeptide Y as the bioactive N-terminal fragment NPY25–36 with central staple or with 
C-terminal addition of spacer and a stapled poly-Lys sequence. These compounds had lower in vitro 
potencies (NPY) or affinities (galanin) than their parent peptides but retained their in vivo activities, 
perhaps due to improved metabolic stability. 
5. Conclusions 
The i,i+4 stapling of the truncated orexin-A15–33 peptide at four different positions (Leu19–Ala23, 
Ala23–Ala27, Asn25–Gly29, and Ala27–Leu31) lowers the potency of the peptide significantly. 
Modifications close to the peptide C-terminus are not tolerated. At the central position (Ala23–
Ala27) spanning the putative small bend, cross-linkers one carbon atom shorter or longer, or simple 
Aib replacements at the same position, also result in decreased potency. The introduced 
modifications clearly lead to poor peptide–receptor recognition and/or impaired activation. This 
might be due to suboptimal peptide conformation or the lack of space for the cross-linker and the 
additional methyl substituent at the α-carbons, or alternatively, the modifications block important 
peptide–receptor interactions either directly or due to helical stabilization, which shields the peptide 
backbone from receptor residues. However, although this does not confirm the active conformation 
of the wild-type orexin-A, our stapled peptides provide evidence that the orexin receptors can be 
activated by α-helical peptides. 
Our study shows that successful conformational stabilization of orexin-A with the stapled peptide 
methodology or other similar cross-linkers, or by introduction of Aib is challenging. However, as 
two of our compounds (3EL and 4A) show, certain modifications are better tolerated. Stapled or 
Aib-modified peptides could be further studied especially for their pharmacokinetic properties such 
as membrane penetration (mainly gut wall and blood–brain barrier), plasma half-life and metabolic 
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stability, as these factors also affect biological activity; however, such studies would require 
development of peptides with higher in vitro activity than the current ones. 
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